Epratuzumab

Epratuzumab is a type of medicine called a monoclonal antibody, designed to target specific immune cells involved in autoimmune diseases like lupus. It works by binding to a protein called CD22 on B cells, a type of immune cell that can mistakenly attack the body's own tissues in such conditions. By attaching to CD22, epratuzumab helps modulate the activity and number of these B cells, reducing inflammation and the immune system’s harmful response. It is used in clinical research to manage autoimmune disorders, aiming to improve symptoms and prevent organ damage.